Impact of a novel cardioprotective agent on the ischaemia-reperfusion- induced Akt kinase activation

Biochemical Pharmacology

Volumn 66, Issue 11, 2003, Pages 2263-2272

  Toth, Ambrus ^a   Kovacs, Krisztina ^a   Deres, Peter ^a   Halmosi, Robert ^a   Czopf, Laszlo ^a   Hanto, Katalin ^a   Kalai, Tamas ^a   Hideg, Kalman ^a   Sumegi, Balazs ^a   Toth, Kalman ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Akt kinase; Cardioprotection; Energy metabolism; Free radicals; Ischaemia reperfusion; Signal transduction

Indexed keywords

CREATINE PHOSPHATE; GLYCOGEN SYNTHASE KINASE 3BETA; HO 3073; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTECTIVE AGENT; PROTEIN KINASE B; SCAVENGER; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME INACTIVATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE FUNCTION; ISOLATED HEART; LIPID PEROXIDATION; MANOMETRY; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

EID: 0242660451     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.007     Document Type: Article

References (40)

1. Martindale J.L., Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 192:2002;1-15.
2. Depre C., Taegtmeyer H. Metabolic aspects of programmed cell survival and cell death in the heart. Cardiovasc. Res. 45:2000;538-548.
3. Piacentini L., Karliner J.S. Altered gene expression during hypoxia and reoxygenation of the heart. Pharmacol. Ther. 83:1999;21-37.
4. Hong F., Kwon S.J., Jhun B.S., Kim S.S., Ha J., Kim S.J., Sohn N.W., Kang C., Kang I. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci. 68:2001;1095-1105.
5. Mockridge J.W., Marber M.S., Heads R.J. Activation of Akt during simulated ischemia/reperfusion in cardiac myocytes. Biochem. Biophys. Res. Commun. 270:2000;947-952.
6. Scheid M.P., Woodgett J.R. PKB/Akt: functional insights from genetic models. Nat. Rev. 2:2001;760-768.
7. Fujio Y., Nguyen T., Wencker D., Kitsis R.N., Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 101:2000;660-667.
8. Jonassen A.K., Sack M.N., Mjos O.D., Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70S6 kinase cell-survival signaling. Circ. Res. 89:2001;1191-1198.
9. Matsui T., Tao J., del Monte F., Li L., Picard M., Force T.L., Franke T.F., Hajjar R.J., Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 104:2001;330-335.
10. Klotz L.O., Schieke S.M., Sies H., Holbrook N.J. Peroxynitrite activates the phosphoinositide 3-kinase/Akt pathway in human skin primary fibroblasts. Biochem. J. 352:2000;219-225.
11. Yamashita K., Kajstura J., Discher D.J., Wasserlauf B.J., Bisphoric N.H., Anversa P., Webster K.A. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ. Res. 88:2001;609-614.
12. Romashkova J.A., Makarov S.S. NF-κB is a target of Akt in anti-apoptotic PDGF signaling. Nature. 401:1999;86-90.
13. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase by Akt dependent phosphorylation. Nature. 399:1999;601-605.
14. Gao F., Gao E., Yue T.L., Ohlstein E.H., Lopez B.L., Christopher T.A., Ma X.L. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 105:2002;1497-1502.
15. Halmosi R., Deres P., Toth A., Berente Z., Kalai T., Sumegi B., Hideg K., Toth K. 2,2,5,5-Tetramethylpyrroline-based compounds in the prevention of oxyradical-induced myocardial damage. J. Cardiovasc. Pharmacol. 40:2002;854-867.
16. Li H., Xu K.Y., Zhou L., Kalai T., Zweier J.L., Hideg K., Kuppusamy P.A. A pyrroline derivative of mexiletine offers marked protection against ischemia/reperfusion-induced myocardial contractile dysfunction. J. Pharmacol. Exp. Ther. 295:2000;563-571.
17. Shankar R.A., Hideg K., Zweier J.L., Kuppusamy P.A. Targeted antioxidant properties of N-[(tetramethyl-3-pyrroline-3-carboxamido)propyl]phthalimide and its nitroxide metabolite in preventing postischemic myocardial injury. J. Pharmacol. Exp. Ther. 292:2000;838-845.
18. Krishna M.C., DeGraff W., Hankovszky O.H., Sar C.P., Kalai T., Jeko J., Russo A., Mitchell J.B., Hideg K. Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage. J. Med. Chem. 41:1998;3477-3492.
19. Marton Z., Halmosi R., Horvath B., Alexy T., Kesmarky G., Vekasi J., Battyany I., Hideg K., Toth K. Scavenger effect of experimental and clinically used cardiovascular drugs. J. Cardiovasc. Pharmacol. 38:2001;745-753.
20. Twomey P., Taira J., DeGraff W., Mitchell J.B., Russo A., Krishna M.C., Hankovszky O.H., Frank L., Hideg K. Direct evidence for in vivo nitroxide free radical production from a new antiarrhythmic drug by EPR spectroscopy. Free Radic. Biol. Med. 22:1997;909-916.
21. Szabados E., Fischer M.G., Gallyas F. Jr., Kispal Gy., Sumegi B. Enhanced ADP-ribosylation and its diminution by lipoamide after ischemia-reperfusion in perfused rat heart. Free Radic. Biol. Med. 27:1999;1103-1113.
22. Varbiro G., Toth A., Tapodi A., Veres B., Sumegi B., Gallyas F. Jr. Concentration dependent mitochondrial effect of amiodarone. Biochem. Pharmacol. 65:2003;1115-1128.
23. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:2000;95-105.
24. De Graaf RA. In vivo NMR spectroscopy. Chichester: Wiley; 1998.
25. + exchange inhibitor, on cardioprotective effect of ischaemic and angiotensin preconditioning. Mol. Cell. Biochem. 214:2000;31-38.
26. Szabados E., Literati-Nagy P., Farkas B., Sumegi B. BGP-15, a nicotinic amidoxime derivative protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem. Pharmacol. 59:2000;937-945.
27. Tzeng W.F., Lee J.L., Chiou T.J. The role of lipid peroxidation in menadione-mediated toxicity in cardiomyocytes. J. Mol. Cell. Cardiol. 27:1995;1999-2008.
28. Butterfield D.A., Howard B.J., Yatin S., Allen K.L., Carney J.M. Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-alpha-phenylnitrone. Proc. Natl. Acad. Sci. U.S.A. 94:1997;674-678.
29. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 6:2000;513-519.
30. Halmosi R., Berente Z., Osz E., Toth K., Literati-Nagy P., Sumegi B. Effect of poly-ADP-ribose-polymerase inhibitors on the ischemia-reperfusion induced oxidative cardiac injury and mitochondrial metabolism in Langendorff heart perfusion system. Mol. Pharmacol. 59:2001;1497-1505.
31. Brazil D.P., Hemmings B.A. Ten years of protein kinase B signalling: a hard Akt to follow. TiBS. 26:2001;657-664.
32. Madge L.A., Pober J.S. A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NFκB in human endothelial cells. J. Biol. Chem. 275:2000;15458-15465.
33. Pap M., Cooper G.M. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β signaling pathway. Mol. Cell. Biol. 22:2002;578-586.
34. Punn A., Mockridge J.W., Farooqui S., Marber M.S., Heads R.J. Sustained activation of p42/p44 mitogen-activated protein kinase during recovery from simulated ischaemia mediates adaptive cytoprotection in cardiomyocytes. Biochem. J. 350:2000;891-899.
35. Adderley S.R., Fitzgerald D.J. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J. Biol. Chem. 274:1999;5038-5046.
36. Tong H., Chen W., Steenbergen C., Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ. Res. 87:2000;309-315.
37. Tobiume K., Matsuzawa A., Takahashi T., Nishitoh H., Morita K., Takeda K., Minowa O., Miyazono K., Noda T., Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO J. 21:2001;222-228.
38. Clerk A., Fuller S.J., Michael A., Sugden P.H. Stimulation of "stress-regulated" mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. J. Biol. Chem. 273:1998;7228-7234.
39. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature. 410:2001;37-40.
40. Kim A.H., Khursigara G., Sun X., Franke T.F., Chao M.V. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol. 21:2001;893-901.